蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 6060|回复: 20
收起左侧

[质量保证QA] 再验证和持续性验证(日常监管/周期性回顾)

[复制链接]
药士
发表于 2015-10-15 22:47:30 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
本帖最后由 beiwei5du 于 2015-10-15 22:48 编辑

Historically, it was considered acceptable to perform periodic revalidation on cleaning processes in lieu of routine monitoring and periodic review. However, the approach of revalidation yields a much less robust picture of the state of control of the cleaning process and may be more resource -intensive. Revalidation as a concept is no longer used by some regulatory agencies because of a preference for alifecycle validation approach. Under a lifecycle validation approach, a significant change in a cleaning process involves not the revalidation of the previous process, but rather validation of a new process.Such validation of a new process, however, may rely on data from the old process based on it being sufficiently similar.

持续性验证(日常监察/周期性回顾)将取代再验证



回复

使用道具 举报

药士
发表于 2015-10-16 06:49:15 | 显示全部楼层
就如GMP检查常态化,持续保持验证状态,比日常不问,定期再验证效果的多
回复

使用道具 举报

药士
发表于 2015-10-16 07:18:50 | 显示全部楼层
中英文对不上
回复

使用道具 举报

发表于 2015-10-16 07:56:33 | 显示全部楼层
英文看不懂,
回复

使用道具 举报

药徒
发表于 2015-10-16 07:57:44 | 显示全部楼层
新版GMP规定有“工艺验证、工艺持续性确认、再验证”,没有说增加了工艺持续性确认,就把再验证取消了!!!只是在时间点上,在验证与再验证之间又增加了一个“持续性确认”

补充内容 (2015-10-17 16:03):
最初3批验证与年度质量回顾之间,增加了持续工艺确认!!
回复

使用道具 举报

药士
 楼主| 发表于 2015-10-16 08:14:49 | 显示全部楼层
wgt-王 发表于 2015-10-16 07:57
新版GMP规定有“工艺验证、工艺持续性确认、再验证”,没有说增加了工艺持续性确认,就把再验证取消了!! ...

这个持续性验证代替再验证,应该是个趋势?
回复

使用道具 举报

药徒
发表于 2015-10-16 08:52:09 | 显示全部楼层
楼主英语水平很高吗
回复

使用道具 举报

大师
发表于 2015-10-16 08:59:59 | 显示全部楼层
持续验证如何具体实施?
回复

使用道具 举报

药徒
发表于 2015-10-16 10:21:29 | 显示全部楼层
学习了,谢谢。
回复

使用道具 举报

药师
发表于 2015-10-16 10:46:48 | 显示全部楼层
学习一下啦,谢谢提供分享。
回复

使用道具 举报

药徒
发表于 2015-10-16 11:02:17 | 显示全部楼层
这个好像与是否取代再验证没啥关系啊!!!我英语不好别忽悠我!
回复

使用道具 举报

药士
 楼主| 发表于 2015-10-16 11:11:15 | 显示全部楼层
尼采 发表于 2015-10-16 08:52
楼主英语水平很高吗

不好!正在学习!
回复

使用道具 举报

药士
 楼主| 发表于 2015-10-16 11:11:59 | 显示全部楼层
十二月的雪 发表于 2015-10-16 11:02
这个好像与是否取代再验证没啥关系啊!!!我英语不好别忽悠我!

我英语不好忽悠你了!
回复

使用道具 举报

药徒
发表于 2015-10-16 11:15:46 | 显示全部楼层
beiwei5du 发表于 2015-10-16 11:11
不好!正在学习!

我都看不懂,还是你厉害
回复

使用道具 举报

药徒
发表于 2015-10-16 13:33:24 | 显示全部楼层
beiwei5du 发表于 2015-10-16 08:14
这个持续性验证代替再验证,应该是个趋势?

应该是两个概念
回复

使用道具 举报

药徒
发表于 2015-10-16 14:45:12 | 显示全部楼层
beiwei5du 发表于 2015-10-16 08:14
这个持续性验证代替再验证,应该是个趋势?

中国的法规是还有再验证的。
大概是偏差、变更引发,持续性确认中有不良趋势引发等
回复

使用道具 举报

药士
 楼主| 发表于 2016-1-13 23:00:47 | 显示全部楼层
Process Validation
The options with regard to process validation have been extended. The previous "traditional" approach is still mentioned as a possibility, though - also with the determination of 3 validation batches. For a 3 batch validation further data from following batches may be necessary according to an "ongoing process verification". The possibility of a "continuous process verification" as described in ICH Q8, and a hybrid approach as a mix of the before mentioned two approaches is new. This is a clear difference to the US FDA Process Validation Guidance where only one approach is mentioned. According to the final EU GMP Annex 15 a "bracketing" approach can be used with respect to the number of runs, strength, batch size, packaging sizes and types. This is already known from the US.

As part of the "ongoing process verification" the product quality should be monitored during the product life cycle to show that the "state of control" is fulfilled and that trends are assessed. This is also known as "Continued Process Verification" from the US. The "ongoing process verification" should be based and reported according to a protocol or equivalent documents, latter is new compared to the draft. Completely omitted has been the subject of a (regular) revalidation.
from<EU GMP Annex 15>
回复

使用道具 举报

药士
 楼主| 发表于 2016-1-13 23:19:38 | 显示全部楼层
本帖最后由 beiwei5du 于 2016-1-13 23:21 编辑

More than half of the participants assessed removing the routine validation (question 8) as understandable as it is replaced by the ongoing process verification. But 36.6% would still like to regularly revalidate based on a risk assessment, and 6.4% even without a risk analysis. Just as many participants will only do this in a sterile area (e.g. at Medial Fills).
The hybrid approach is also only clear to just under 50% of participants. With the request for ongoing process verification, the majority of the industry (60.4%) believes this will result in additional work, while 50% also believe discontinuing the routine revalidation will result in additional work.


from<Validation - Revision of Annex 15: How does the Industry see the Changes? - Results of an ECA Survey>


Other important changes compared to the current version are:

  • There are new terms that are not explained in the glossary, such as "ongoing validation strategy"
  • Retrospective validation and the notion of revalidation are gone completely - except  for one exemption
  • from<Revision of the EU GMP Annex 15 for Qualification and Validation published>

form<Revision of the EU GMP Annex 15 for Qualification and Validation published>

回复

使用道具 举报

药徒
发表于 2020-10-22 16:58:17 | 显示全部楼层
long long ago.More and More
回复

使用道具 举报

发表于 2022-6-14 08:35:05 | 显示全部楼层
谢谢分享 学习了 !
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-5-8 19:35

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表